Supplement Aims and Scope
This supplement is intended to focus on biomarkers for colon cancer. Biomarkers of survival in colon cancer, detection of new colon cancer biomarkers in tissues and body fluids, and new methods for the detection and elimination of micrometastases in colon cancer are included within the supplement’s scope.
Biomarkers in Cancer aims to provide researchers working in this complex, quickly developing field with online, open access to highly relevant scholarly articles by leading international researchers. In a field where the literature is ever-expanding, researchers increasingly need access to up-to-date, high quality scholarly articles on areas of specific contemporary interest. This supplement aims to address this by presenting high-quality articles that allow readers to distinguish the signal from the noise. The editor in chief hopes that through this effort, practitioners and researchers will be aided in finding answers to some of the most complex and pressing issues of our time.
Articles should focus on biomarkers for colon cancer and may include the following topics:
- ▪ Biomarkers of survival in colon cancer
- ▪ Good prognosis indicators, micrometastases and their detection, genetic epidemiology.
- ▪ Detection of new colon cancer biomarkers—in tissues and body fluids
- ▪ miRNAs, proteomics, antibody arrays.
- ▪ New methods for the detection and elimination of micrometastases in colon cancer
- ▪ Histology (sentinel lymph nodes), fluorescence navigation (blood), RT-PCR.
This supplement focuses on biomarkers for colorectal cancer, a common and often deadly cancer in the world.
In an era of personalized medicine, identification as well as use of biomarkers for decision-making is crucial. Biomarkers could be of three different natures: diagnostic, predictive, and prognostic. Diagnostic biomarkers serve to determine the nature of a tumor, which could further help decision-making about the treatment to choose while prognostic biomarkers predict the survival outcomes of patients. Predictive biomarkers, on the other hand, can be used to predict response to specific treatments. An example of successful predictive biomarker is the G12D KRAS mutation in CRC.1 It is now well established that patients with this mutation do not benefit from adjuvant therapy with the anti-EGFR monoclonal antibody named cetuximab.1 Prognostic and diagnostic biomarkers are potentially predictive markers too, and this link remains to be examined in detail by future studies.
Not surprisingly, research leading to biomarker identification is crucial. Two contributions in this supplement review and discuss the importance of biomarkers in CRC. The group of Dr. Klampfer reviews the prognostic and predictive role of stromal biomarkers, and more generally the importance of the tumor microenvironment in tumoral development. The other study published by Dr. Mousa and colleagues focuses on angiogenesis, which is one of the therapeutic targets in CRC.2 These authors discuss arising predictive angiogenic biomarkers that may help select subsets of patients who can benefit from angiogenesis inhibition.
Other contributions in this supplement discuss genetic factors as potential biomarkers in CRC. For example, Dr. Barras discusses the importance of the V600E BRAF mutation and its prognostic role in CRC. The BRAF mutant melanomas are efficiently treated with BRAF inhibitors, while BRAF mutant CRCs display resistance to such therapies. This perplexing fact is also discussed by Dr. Barras. Another example is the meta-analysis by Dr. Pabalan and colleagues that focuses on the role of a polymorphism in the methionine synthase reductase (MTRR) as a risk factor for CRC. MTRR plays a crucial role in the folate biosynthesis, which is linked to DNA synthesis. Abnormalities in this process may have cancer-promoting effects. This article shows that the A allele polymorphism which is significantly more present in the Asian population, confers protective effects against tumoral development.
A research article published by Dr. Ghanbari and collaborators complements this CRC biomarker issue. They present their findings that microRNAs detected in feces, let-7a-5p and let-7f-5p, are under-expressed and are biomarkers for early stage CRC. This finding has potential for the detection of early stage CRCs, which allows to treat patient before the tumor becomes advanced.
As the studies compiled in this supplemental issue highlight, biomarker research in colorectal cancer is progressing at different fronts and hold promise for better understanding and management of this disease in the future.
We invite our readers to take a look at these articles for more details.
Lead Guest Editor Dr. David Barras
Bioinformatician at the Swiss Institute of Bioinformatics in the Bio-informatics Core Facility. He completed his PhD in molecular biology at the University of Lausanne. He now works primarily in bioinformatics and biostatistics. Dr Barras is the first author of six published papers.
david.barras@unil.ch
Institutional webpage
Guest Editor
DR. SEVTAP SAVAS
Associate Professor of Genetics and Oncology at Memorial University. She completed her PhD at Bogazici University and has previously worked at Princess Margaret Hospital & Mount Sinai Hospital, Toronto and Louisiana State University, USA. She now works primarily in genetic basis of outcome risk in cancer patients. Dr. Savas is the author or co-author of more than 40 published and peer-reviewed papers and has presented at several conferences, and holds editorial appointments at a number of journals.
savas@mun.ca
Institutional webpage
https://www.med.mun.ca/Medicine/Faculty/Savas,-Sevtap.aspx
Footnotes
FUNDING: Authors disclose no external funding sources.
COMPETING INTERESTS: Authors disclose no potential conflicts of interest.
All authors have provided signed confirmation of their compliance with ethical and legal obligations including (but not limited to) use of any copyrighted material, compliance with ICMJE authorship and competing interests disclosure guidelines.
REFERENCES
- 1.Lievre A, Bachet JB, Le CD, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995. doi: 10.1158/0008-5472.CAN-06-0191. [DOI] [PubMed] [Google Scholar]
- 2.Salmon JS, Lockhart AC, Berlin J. Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest. 2005;23(8):712–726. doi: 10.1080/07357900500360024. [DOI] [PubMed] [Google Scholar]